Patients with advanced Hodgkin’s Lymphoma (HL) have been with the combination of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and have largely positive outcomes. Recent clinical trial evidence suggests that a new therapy, brentuximab vedotin might confer additional benefits compared to standard therapy. This project explores whether brentuximab vedotin is cost-effective when compared to established therapy in patients with advanced HL.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.